DyNAbind
DyNAbind is a biotechnology company based in Germany offering drug discovery partnerships which leverage its proprietary platform of DNA-Encoded Dynamic Library technologies.
DyNAbind libraries are designed with meaningful drug development in mind, offering only quality-controlled hit compounds across a massive amount of fragment and small molecule chemical space, all favorable for medicinal chemistry development.
Combined with patented suite of technologies to improve data quality, reliability and speed of downstream analysis and triage, DyNAbind is positioned to be a partner for rapid discovery of higher-quality hits.
WuXi AppTec
WuXi AppTec is a leading pharmaceutical and medical device open-access capability and technology platform Company with global operations.
As an innovation-driven and customer-focused Company, WuXi AppTec provides a broad and integrated portfolio of services to help our worldwide customers and partners to shorten the discovery and development time and lower the cost of drug and medical device R&D through cost-effective and efficient solutions.
With its industry-leading capabilities such as small molecule R&D and manufacturing, cell therapy and gene therapy R&D and manufacturing, and drug R&D and medical device testing, the WuXi platform is enabling nearly 3,000 innovative collaborators from more than 30 countries to bring innovative healthcare products to patients, and to fulfill WuXi’s dream that “every drug can be made and every disease can be treated.”
The WuXi DNA-Encoded Library (DEL) platform is a fast-growing, cutting-edge hit discovery platform that provides easily accessible DEL technology and services to anyone and any Company in the drug discovery field. With an expert team, unique and exclusive chemical reactions and scaffolds, a customized screening strategy and novel informatics, WuXi has created a world-class DNA encoded library operation. Supported by the full spectrum of WuXi AppTec services, the WuXi DEL platform offers one of the most flexible business model at competitive prices.
WuXi AppTec currently provides easy access to 80 Billion DNA-Encoded Small Molecules Libraries
X-CHEM
Established in 2009 by Richard Wagner, Brant Binder and Gordon Binder and located in Waltham (US), X-Chem primarily offers DNA-conjugate library technology services for the identification of biologically active small organic ligands. Their expertise covers a wide range of pharmaceutical target proteins, including protein/protein interaction (PPI), antibacterial and GPCR.
They have have established collaborations with several of the leading pharmaceutical companies in the world. X-Chem has been acquired by GHO Capital Partners LLP (GHO) in 2020.
Nuevolution
– sponsored page –